146 related articles for article (PubMed ID: 12907624)
41. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
[TBL] [Abstract][Full Text] [Related]
42. Tumor-reactive, SSX-2-specific CD8+ T cells are selectively expanded during immune responses to antigen-expressing tumors in melanoma patients.
Ayyoub M; Rimoldi D; Guillaume P; Romero P; Cerottini JC; Valmori D; Speiser D
Cancer Res; 2003 Sep; 63(17):5601-6. PubMed ID: 14500401
[TBL] [Abstract][Full Text] [Related]
43. Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice.
Lladser A; Párraga M; Quevedo L; Carmen Molina M; Silva S; Ferreira A; Billetta R; G Quest AF
Immunobiology; 2006; 211(1-2):11-27. PubMed ID: 16446167
[TBL] [Abstract][Full Text] [Related]
44. Suboptimal SARS-CoV-2-specific CD8
Habel JR; Nguyen THO; van de Sandt CE; Juno JA; Chaurasia P; Wragg K; Koutsakos M; Hensen L; Jia X; Chua B; Zhang W; Tan HX; Flanagan KL; Doolan DL; Torresi J; Chen W; Wakim LM; Cheng AC; Doherty PC; Petersen J; Rossjohn J; Wheatley AK; Kent SJ; Rowntree LC; Kedzierska K
Proc Natl Acad Sci U S A; 2020 Sep; 117(39):24384-24391. PubMed ID: 32913053
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells.
Nitschke NJ; Bjoern J; Met O; Svane IM; Andersen MH
Scand J Immunol; 2016 Sep; 84(3):191-3. PubMed ID: 27354164
[No Abstract] [Full Text] [Related]
46. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
47. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
[TBL] [Abstract][Full Text] [Related]
48. Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.
Hamrouni S; Bras-Gonçalves R; Kidar A; Aoun K; Chamakh-Ayari R; Petitdidier E; Messaoudi Y; Pagniez J; Lemesre JL; Meddeb-Garnaoui A
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008093. PubMed ID: 32176691
[TBL] [Abstract][Full Text] [Related]
49. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma.
Rimoldi D; Rubio-Godoy V; Dutoit V; Lienard D; Salvi S; Guillaume P; Speiser D; Stockert E; Spagnoli G; Servis C; Cerottini JC; Lejeune F; Romero P; Valmori D
J Immunol; 2000 Dec; 165(12):7253-61. PubMed ID: 11120859
[TBL] [Abstract][Full Text] [Related]
50. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma.
Tatsumi T; Herrem CJ; Olson WC; Finke JH; Bukowski RM; Kinch MS; Ranieri E; Storkus WJ
Cancer Res; 2003 Aug; 63(15):4481-9. PubMed ID: 12907621
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
[TBL] [Abstract][Full Text] [Related]
52. Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes.
Dangles V; Halberstam I; Scardino A; Choppin J; Wertheimer M; Richon S; Quelvennec E; Moirand R; Guillet JG; Kosmatopoulos K; Bellet D; Zeliszewski D
Cancer Immunol Immunother; 2002 Feb; 50(12):673-81. PubMed ID: 11862419
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
54. Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes.
Siegel S; Steinmann J; Schmitz N; Stuhlmann R; Dreger P; Zeis M
Leukemia; 2004 Dec; 18(12):2046-7. PubMed ID: 15470490
[No Abstract] [Full Text] [Related]
55. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
[TBL] [Abstract][Full Text] [Related]
56. Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia.
Sohn HJ; Lee JY; Lee HJ; Sohn DH; Cho HI; Kim HJ; Kim TG
Oncotarget; 2017 Jul; 8(27):44059-44072. PubMed ID: 28477011
[TBL] [Abstract][Full Text] [Related]
57. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
58. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8
Boudousquie C; Bossi G; Hurst JM; Rygiel KA; Jakobsen BK; Hassan NJ
Immunology; 2017 Nov; 152(3):425-438. PubMed ID: 28640942
[TBL] [Abstract][Full Text] [Related]
59. Synthetic tumor-specific antigenic peptides with a strong affinity to HLA-A2 elicit anti-breast cancer immune response through activating CD8
Shi W; Qiu Q; Tong Z; Guo W; Zou F; Feng Z; Wang Y; Huang W; Qian H
Eur J Med Chem; 2020 Mar; 189():112051. PubMed ID: 31968280
[TBL] [Abstract][Full Text] [Related]
60. Identification of HLA DR7-restricted epitopes from human telomerase reverse transcriptase recognized by CD4+ T-helper cells.
Schroers R; Huang XF; Hammer J; Zhang J; Chen SY
Cancer Res; 2002 May; 62(9):2600-5. PubMed ID: 11980655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
